淀粉样蛋白PET联合FDG PET预测临床实践中轻度认知障碍短期转化为阿尔茨海默病
研究纳入145例遗忘型轻度认知障碍(aMCI)患者,按淀粉样蛋白PET(A)和FDG PET(N)阳性或阴性分为四组并临床随访至进展为阿尔茨海默病(AD)痴呆。淀粉样蛋白PET阴性者进展较阳性者慢(75.07个月 vs 32.59个月),A+/N+者较A+/N-者转化更快(27.79个月 vs 37.38个月),提示联合两种生物标志物可提高短期转化预测。
要点
- 淀粉样蛋白PET阴性aMCI进展至AD慢于阳性者(75.07个月 vs 32.59个月)。
- A+/N+患者转化快于A+/N-患者(27.79个月 vs 37.38个月)。
- 联合淀粉样蛋白PET与FDG PET可提高短期转化预测。
核心结论
- 在aMCI患者中,淀粉样蛋白PET阳性且FDG PET呈AD模式者较仅淀粉样蛋白PET阳性者显著更早进展为痴呆。
- 初始诊断时联合使用两种生物标志物可提高短期转化的预测。
研究设计与样本
- 研究于2013年10月至2021年3月招募145例aMCI患者。
- 按淀粉样蛋白PET(A)和FDG PET(N)阳性(+)或阴性(-)将患者分为四组,并进行临床随访以确定是否进展为AD所致痴呆。
主要发现
- 淀粉样蛋白PET第1年灵敏度100%、第4年94.67%,阴性预测值第1年100%、第4年88.24%。
- FDG PET第1年阴性预测值94.59%,随访期间特异度(85%)和阳性预测值(88%)均升高。
- aMCI转化为AD的总体平均时间为39.95个月。
- 淀粉样蛋白阴性患者进展至AD较阳性患者慢(75.07个月[CI 56.54-81] vs 32.59个月[CI 20.56-40.74])。
- A+/N+患者转化时间较A+/N-患者快(27.79个月[CI 20.40-33.21] vs 37.38个月[CI 20.73-48.26])。
关键数值与推荐
- 淀粉样蛋白PET第1年灵敏度100%、第4年94.67%;阴性预测值第1年100%、第4年88.24%。
- FDG PET第1年阴性预测值94.59%;随访期间特异度85%、阳性预测值88%。
- aMCI转化为AD总体平均时间39.95个月。
- 淀粉样蛋白阴性 vs 阳性患者进展时间75.07个月[CI 56.54-81] vs 32.59个月[CI 20.56-40.74]。
- A+/N+ vs A+/N-患者转化时间27.79个月[CI 20.40-33.21] vs 37.38个月[CI 20.73-48.26]。
临床怎么用
- 原文结论认为,在aMCI患者初始诊断时联合使用淀粉样蛋白PET和FDG PET可提高对短期转化为AD的预测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Amnestic mild cognitive impairment (aMCI) is considered a precursor to Alzheimer's disease (AD). Since cerebral amyloid aggregation and neurodegeneration can be detected at an early stage, it can serve as a diagnostic aid. This study aimed to determine the predictive value of Amyloid-PET and FDG-PET in determining progression to AD among patients with aMCI. METHODS: This study recruited 145 patients with aMCI from October 2013 to March 2021. The patients were classified into four groups based on whether Amyloid-PET (A) and FDG-PET (N) were positive (+) or negative (-). The patients were then clinically followed to establish progression to dementia due to AD. RESULTS: Amyloid-PET demonstrated high sensitivity (100% in year 1, 94.67% in year 4) and a high negative predictive value (100% in year 1, 88.24% in year 4). FDG-PET exhibited a high negative predictive value initially (94.59% in year 1), and during follow-up, both specificity (85%) and positive predictive value (88%) increased. The conversion from aMCI to AD had a global mean time of 39.95 months. However, progression to AD was slower in amyloid-negative patients versus amyloid-positive patients (75.07 [CI 56.54-81] vs. 32.59 months [CI 20.56-40.74] months). Taking both tests together, the time to conversion was faster in A+/N + versus A+/N- patients (27.79 [CI 20.40-33.21] vs. 37.38 [CI 20.73-48.26] months). CONCLUSIONS: Among patients with aMCI, those with a positive Amyloid-PET and an AD pattern on FDG-PET progressed to dementia significantly earlier versus those with a positive Amyloid-PET only. Using both biomarkers during the initial diagnosis enhances the prediction of short-term conversion. CLINICAL TRIAL NUMBER: Not applicable. It is not a clinical trial.
引用
- Echeveste B, Prieto E, Guillén EF, et al. Combination of amyloid and FDG PET for the prediction of short-term conversion from MCI to Alzheimer´s disease in the clinical practice. Eur J Nucl Med Mol Imaging. 2025. PMID: 40257609. doi:10.1007/s00259-025-07275-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。